Clinical Trial

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Study acronym: inMMyCAR
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Protocol Amendment History 2 changes
notable Trial sites expanded: 7 -> 10 locations 2026-07-09
notable Enrollment increased: 40 -> 70 participants 2026-04-25
Trial Details
NCT Number NCT07075185
Lead Sponsor Kelonia Therapeutics, Inc.
Conditions Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type, Neoplasm, Hemostatic Disorders, Vascular Disorder, Paraproteinemias +6 more
Enrollment 70 participants
Start Date 2025-07-16
Primary Completion 2027-03 (estimated)
Study Completion 2042-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-08